The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6627-6638

  Mesa Arango, Ana Cecilia ^a,b   Trevijano Contador, Nuria ^a   Román, Elvira ^c   Sánchez Fresneda, Ruth ^d   Casas, Celia ^e   Herrero, Enrique ^e   Argüelles, Juan Carlos ^d   Pla, Jesús ^c   Cuenca Estrella, Manuel ^a   Zaragoza, Oscar ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF MURCIA   (Spain)

^e UNIVERSITY OF LLEIDA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CATALASE; FUNGICIDE; REACTIVE OXYGEN METABOLITE; ROTENONE; ANTIFUNGAL AGENT; ERGOSTEROL; UNCOUPLING PROTEIN;

ARTICLE; BREATHING RATE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CELL DEATH; CONTROLLED STUDY; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RESPIRATORY BURST; RESPIRATORY CHAIN; ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDIASIS; CELL MEMBRANE; CRYPTOCOCCOSIS; DRUG EFFECTS; ELECTRON TRANSPORT; FILOBASIDIELLA; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; OXYGEN CONSUMPTION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CATALASE; CELL MEMBRANE; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG RESISTANCE, FUNGAL; ELECTRON TRANSPORT; ERGOSTEROL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROBIAL SENSITIVITY TESTS; OXIDATIVE STRESS; OXYGEN CONSUMPTION; REACTIVE OXYGEN SPECIES; ROTENONE; UNCOUPLING AGENTS;

EID: 84908280203     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03570-14     Document Type: Article

References (94)

1. Oura M, Sternberg TH, Wright ET. 1955. A new antifungal antibiotic, amphotericin B. Antibiot. Annu. 3:566-573.
2. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE. 2000. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30:710-718. http://dx.doi.org/10.1086/313757.
3. Waness A, Dawsari GA, Al Jahdali H. 2009. The rise of an opportunistic infection called "invasive zygomycosis." J. Glob. Infect. Dis. 1:131-138. http://dx.doi.org/10.4103/0974-777X.56256.
4. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 18(Suppl 7):S19-S37. http://dx.doi.org/10.1111/1469-0691.12039.
5. Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, ESCMID EFISG Study Group, ECMM. 2013. ESCMID and ECMM joint clinical guideline for the diagnosis and management of rare invasive yeast infections. Clin. Microbiol. Infect. 20(Suppl 3):76-98. http://dx.doi.org/10.1111/1469-0691.12360.
6. Gómez-López A, Zaragoza O, Rodríguez-Tudela JL, Cuenca-Estrella M. 2008. Pharmacotherapy of yeast infections. Expert Opin. Pharmacother 9:2801-2816. http://dx.doi.org/10.1517/14656566.9.16.2801.
7. Fortún J, Carratalá J, Gavaldá J, Lizasoain M, Salavert M, de la Cámara Borges R, Cervera M, Garnacho A, Lassaleta, Á, Lumbreras C, Sanz MÁ, Ramos JT, Torre-Cisneros J, Aguado JM, Cuenca-Estrella M, Grupo de Estudio de Micología Médica de la SEIMC (GEMICOMED). 2011. Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update. Enferm. Infecc. Microbiol. Clin. 29:435-454. (In Spanish.) http://dx.doi.org/10.1016/j.eimc.2011.01.010.
8. Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Herbrecht R, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin. Microbiol. Infect. 18(Suppl 7):S38-S52. http://dx.doi.org/10.1111/1469-0691.12040.
9. Filioti I, Iosifidis E, Roilides E. 2008. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opin. Pharmacother. 9:3179-3196. http://dx.doi.org/10.1517/14656560802560005.
10. Turkova A, Roilides E, Sharland M. 2011. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy-is there a 'right' choice? Curr. Opin. Infect. Dis. 24:163-171. http://dx.doi.org/10.1097/QCO.0b013e328343614e.
11. Hsuchen CC, Feingold DS. 1973. Selective membrane toxicity of the polyene antibiotics: studies on natural membranes. Antimicrob. Agents Chemother. 4:316-319. http://dx.doi.org/10.1128/AAC.4.3.316.
12. Laniado-Laborín R, Cabrales-Vargas MN. 2009. Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 26:223-227. http://dx.doi.org/10.1016/j.riam.2009.06.003.
13. Mesa-Arango AC, Scorzoni L, Zaragoza O. 2012. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front. Microbiol. 3:286. http://dx.doi.org/10.3389/fmicb.2012.00286.
14. Sabra R, Branch RA. 1990. Amphotericin B nephrotoxicity. Drug Saf. 5:94-108. http://dx.doi.org/10.2165/00002018-199005020-00003.
15. Saliba F, Dupont B. 2008. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med. Mycol. 46:97-112. http://dx.doi.org/10.1080/13693780701730469.
16. Dupont B. 2002. Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. 49(Suppl 1):S31-S36. http://dx.doi.org/10.1093/jac/49.suppl-1.31.
17. Gulati M, Bajad S, Singh S, Ferdous AJ, Singh M. 1998. Development of liposomal amphotericin B formulation. J. Microencapsul. 15:137-151. http://dx.doi.org/10.3109/02652049809006844.
18. Meunier F, Prentice HG, Ringdén O. 1991. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28(Suppl B):83-91.
19. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. 2008. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 97:2405-2425. http://dx.doi.org/10.1002/jps.21179.
20. Veerareddy PR, Vobalaboina V. 2004. Lipid-based formulations of amphotericin B. Drugs Today (Barc.) 40:133-145. http://dx.doi.org/10.1358/dot.2004.40.2.799425.
21. Moen MD, Lyseng-Williamson KA, Scott LJ. 2009. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392. http://dx.doi.org/10.2165/00003495-200969030-00010.
22. Gottlieb D, Carter HE, Sloneker JH, Ammann A. 1958. Protection of fungi against polyene antibiotics by sterols. Science 128:361. http://dx.doi.org/10.1126/science.128.3320.361.
23. Gottlieb D, Carter HE, Sloneker JH, Wu LC, Gaudy E. 1961. Mechanisms of inhibition of fungi by filipin. Phytopathology 51:321-330.
24. Lampen JO, Arnow PM, Borowska Z, Laskin AI. 1962. Location and role of sterol at nystatin-binding sites. J. Bacteriol. 84:1152-1160.
25. Kinsky SC. 1962. Nystatin binding by protoplasts and a particulate fraction of Neurospora crassa, and a basis for the selective toxicity of polyene antifungal antibiotics. Proc. Natl. Acad. Sci. U. S. A. 48:1049-1056. http://dx.doi.org/10.1073/pnas.48.6.1049.
26. Finkelstein A, Holz R. 1973. Aqueous pores created in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B. Membranes 2:377-408.
27. Chen WC, Chou DL, Feingold DS. 1978. Dissociation between ion permeability and the lethal action of polyene antibiotics on Candida albicans. Antimicrob. Agents Chemother. 13:914-917. http://dx.doi.org/10.1128/AAC.13.6.914.
28. Cereghetti DM, Carreira EM. 2006. Amphotericin B: 50 years of chemistry and biochemistry. Synthesis 6:914-942. http://dx.doi.org/10.1055/s-2006-926368.
29. Volmer AA, Szpilman AM, Carreira EM. 2010. Synthesis and biological evaluation of amphotericin B derivatives. Nat. Prod. Rep. 27:1329-1349. http://dx.doi.org/10.1039/b820743g.
30. Szpilman AM, Manthorpe JM, Carreira EM. 2008. Synthesis and biological studies of 35-deoxy amphotericin B methyl ester. Angew. Chem. Int. Ed. Engl. 47:4339-4342. http://dx.doi.org/10.1002/anie.200800590.
31. Byrne B, Carmody M, Gibson E, Rawlings B, Caffrey P. 2003. Biosynthesis of deoxyamphotericins and deoxyamphoteronolides by engineered strains of Streptomyces nodosus. Chem. Biol. 10:1215-1224. http://dx.doi.org/10.1016/j.chembiol.2003.12.001.
32. Carmody M, Murphy B, Byrne B, Power P, Rai D, Rawlings B, Caffrey P. 2005. Biosynthesis of amphotericin derivatives lacking exocyclic carboxyl groups. J. Biol. Chem. 280:34420-34426. http://dx.doi.org/10.1074/jbc.M506689200.
33. Palacios DS, Anderson TM, Burke MD. 2007. A post-PKS oxidation of the amphotericin B skeleton predicted to be critical for channel formation is not required for potent antifungal activity. J. Am. Chem. Soc. 129:13804-13805. http://dx.doi.org/10.1021/ja075739o.
34. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, Burke MD. 2012. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. U. S. A. 109:2234-2239. http://dx.doi.org/10.1073/pnas.1117280109.
35. Sokol-Anderson ML, Brajtburg J, Medoff G. 1986. Amphotericin B-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. 154:76-83. http://dx.doi.org/10.1093/infdis/154.1.76.
36. Phillips AJ, Sudbery I, Ramsdale M. 2003. Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc. Natl. Acad. Sci. U. S. A. 100:14327-14332. http://dx.doi.org/10.1073/pnas.2332326100.
37. Sangalli-Leite F, Scorzoni L, Mesa-Arango AC, Casas C, Herrero E, Gianinni MJ, Rodríguez-Tudela JL, Cuenca-Estrella M, Zaragoza O. 2011. Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect. 13:457-467. http://dx.doi.org/10.1016/j.micinf.2011.01.015.
38. Belenky P, Camacho D, Collins JJ. 2013. Fungicidal drugs induce a common oxidative-damage cellular death pathway. Cell Rep. 3:350-358. http://dx.doi.org/10.1016/j.celrep.2012.12.021.
39. Liu TT, Lee RE, Barker KS, Wei L, Homayouni R, Rogers PD. 2005. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 49:2226-2236. http://dx.doi.org/10.1128/AAC.49.6.2226-2236.2005.
40. Ben-Ami R, Lewis RE, Kontoyiannis DP. 2008. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin. Infect. Dis. 47:226-235. http://dx.doi.org/10.1086/589290.
41. Turrens JF. 2003. Mitochondrial formation of reactive oxygen species. J. Physiol. 552:335-344. http://dx.doi.org/10.1113/jphysiol.2003.049478.
42. Sena LA, Chandel NS. 2012. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 48:158-167. http://dx.doi.org/10.1016/j.molcel.2012.09.025.
43. Thannickal VJ, Fanburg BL. 2000. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 279:L1005-L1028.
44. Farber JL. 1994. Mechanisms of cell injury by activated oxygen species. Environ. Health Perspect. 102(Suppl 10):S17-S24.
45. Stefanatos R, Sanz A. 2011. Mitochondrial complex I: a central regulator of the aging process. Cell Cycle 10:1528-1532. http://dx.doi.org/10.4161/cc.10.10.15496.
46. Lamy-Freund MT, Ferreira VF, Schreier S. 1985. Mechanism of inactivation of the polyene antibiotic amphotericin B. Evidence for radical formation in the process of autooxidation. J. Antibiot. (Tokyo) 38:753-757.
47. Osaka K, Ritov VB, Bernardo JF, Branch RA, Kagan VE. 1997. Amphotericin B protects cis-parinaric acid against peroxyl radical-induced oxidation: amphotericin B as an antioxidant. Antimicrob. Agents Chemother. 41:743-747.
48. Osaka K, Tyurina YY, Dubey RK, Tyurin VA, Ritov VB, Quinn PJ, Branch RA, Kagan VE. 1997. Amphotericin B as an intracellular antioxidant: protection against 2,2=-azobis(2,4-dimethylvaleronitrile)-induced peroxidation of membrane phospholipids in rat aortic smooth muscle cells. Biochem. Pharmacol. 54:937-945. http://dx.doi.org/10.1016/S0006-2952(97)00267-0.
49. Brajtburg J, Elberg S, Schwartz DR, Vertut-Croquin A, Schlessinger D, Kobayashi GS, Medoff G. 1985. Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob. Agents Chemother. 27:172-176. http://dx.doi.org/10.1128/AAC.27.2.172.
50. Brajtburg J, Elberg S, Kobayashi GS, Medoff G. 1989. Effects of ascorbic acid on the antifungal action of amphotericin B. J. Antimicrob. Chemother. 24:333-337. http://dx.doi.org/10.1093/jac/24.3.333.
51. Forastiero A, Mesa-Arango AC, Alastruey-Izquierdo A, Alcazar-Fuoli L, Bernal-Martinez L, Pelaez T, Lopez JF, Grimalt JO, Gomez-Lopez A, Cuesta I, Zaragoza O, Mellado E. 2013. Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrob. Agents Chemother. 57:4769-4781. http://dx.doi.org/10.1128/AAC.00477-13.
52. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, EUCAST-AFST. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
53. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405. http://dx.doi.org/10.1111/j.1469-0691.2007.01935.x.
54. Bellí G, Molina MM, García-Martínez J, Perez-Ortín JE, Herrero E. 2004. Saccharomyces cerevisiae glutaredoxin 5-deficient cells subjected to continuous oxidizing conditions are affected in the expression of specific sets of genes. J. Biol. Chem. 279:12386-12395. http://dx.doi.org/10.1074/jbc.M311879200.
55. Cabiscol E, Piulats E, Echave P, Herrero E, Ros J. 2000. Oxidative stress promotes specific protein damage in Saccharomyces cerevisiae. J. Biol. Chem. 275:27393-27398. http://dx.doi.org/10.1074/jbc.M003140200.
56. 2 and the acquisition of oxidative tolerance in Candida albicans. Yeast 20:1161-1169. http://dx.doi.org/10.1002/yea.1029.
57. Aebi H. 1984. Catalase in vitro. Methods Enzymol. 105:121-126. http://dx.doi.org/10.1016/S0076-6879(84)05016-3.
58. Sun N, Fonzi W, Chen H, She X, Zhang L, Zhang L, Calderone R. 2013. Azole susceptibility and transcriptome profiling in Candida albicans mitochondrial electron transport chain complex I mutants. Antimicrob. Agents Chemother. 57:532-542. http://dx.doi.org/10.1128/AAC.01520-12.
59. Alonso-Monge R, Carvaihlo S, Nombela C, Rial E, Pla J. 2009. The Hog1 MAP kinase controls respiratory metabolism in the fungal pathogen Candida albicans. Microbiology 155:413-423. http://dx.doi.org/10.1099/mic.0.023309-0.
60. Helmerhorst EJ, Breeuwer P, van't Hof W, Walgreen-Weterings E, Oomen LC, Veerman EC, Amerongen AV, Abee T. 1999. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J. Biol. Chem. 274:7286-7291. http://dx.doi.org/10.1074/jbc.274.11.7286.
61. Oliver BG, Silver PM, Marie C, Hoot SJ, Leyde SE, White TC. 2008. Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology 154:960-970. http://dx.doi.org/10.1099/mic.0.2007/013805-0.
62. Kerscher SJ. 2000. Diversity and origin of alternative NADH:ubiquinone oxidoreductases. Biochim. Biophys. Acta 1459:274-283. http://dx.doi.org/10.1016/S0005-2728(00)00162-6.
63. Kot EJ, Olson VL, Rolewic LJ, McClary DO. 1976. An alternate respiratory pathway in Candida albicans. Antonie Van Leeuwenhoek 42:33-48. http://dx.doi.org/10.1007/BF00399447.
64. Haido RM, Barreto-Bergter E. 1989. Amphotericin B-induced damage of Trypanosoma cruzi epimastigotes. Chem. Biol. Interact. 71:91-103. http://dx.doi.org/10.1016/0009-2797(89)90092-6.
65. Guinea J, Zaragoza O, Escribano P, Martín-Mazuelos E, Pemán J, Sánchez-Reus F, Cuenca-Estrella M, CANDIPOP Project, GEIH-GEMICOMED (SEIMC), REIPI. 2014. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob. Agents Chemother. 58:1529-1537. http://dx.doi.org/10.1128/AAC.02155-13.
66. Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S. 2013. Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol. 11:e1001692. http://dx.doi.org/10.1371/journal.pbio.1001692.
67. Hoehamer CF, Cummings ED, Hilliard GM, Rogers PD. 2010. Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents. Antimicrob. Agents Chemother. 54:1655-1664. http://dx.doi.org/10.1128/AAC.00756-09.
68. De Brucker K, Bink A, Meert E, Cammue BP, Thevissen K. 2013. Potentiation of antibiofilm activity of amphotericin B by superoxide dismutase inhibition. Oxid. Med. Cell. Longev. 2013:704654. http://dx.doi.org/10.1155/2013/704654.
69. Geraghty P, Kavanagh K. 2003. Disruption of mitochondrial function in Candida albicans leads to reduced cellular ergosterol levels and elevated growth in the presence of amphotericin B. Arch. Microbiol. 179:295-300. http://dx.doi.org/10.1007/s00203-003-0530-y.
70. Sarinová M, Straková V, Balková K, Gbelská Y. 2007. Decreased susceptibility to antifungals in respiratory-deficient Kluyveromyces lactis mutants. Folia Microbiol. (Praha) 52:484-490. http://dx.doi.org/10.1007/BF02932108.
71. Zumbuehl A, Jeannerat D, Martin SE, Sohrmann M, Stano P, Vigassy T, Clark DD, Hussey SL, Peter M, Peterson BR, Pretsch E, Walde P, Carreira EM. 2004. An amphotericin B-fluorescein conjugate as a powerful probe for biochemical studies of the membrane. Angew. Chem. Int. Ed. Engl. 43:5181-5185. http://dx.doi.org/10.1002/anie.200460489.
72. Adler-Moore J. 1994. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14(Suppl 5):S3-S7.
73. Zinser E, Daum G. 1995. Isolation and biochemical characterization of organelles from the yeast, Saccharomyces cerevisiae. Yeast 11:493-536. http://dx.doi.org/10.1002/yea.320110602.
74. Drutz DJ, Lehrer RI. 1978. Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am. J. Med. Sci. 276:77-92.
75. Kim SJ, Kwon-Chung KJ. 1974. Polyene-resistant mutants of Aspergillus fennelliae: sterol content and genetics. Antimicrob. Agents Chemother. 6:102-113. http://dx.doi.org/10.1128/AAC.6.1.102.
76. Kim SJ, Kwon-Chung KJ, Milne GWA, Prescott B. 1974. Polyene-resistant mutants of Aspergillus fennelliae: identification of sterols. Antimicrob. Agents Chemother. 6:405-410. http://dx.doi.org/10.1128/AAC.6.4.405.
77. Woods RA, Bard M, Jackson IE, Drutz DJ. 1974. Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. J. Infect. Dis. 129:53-58. http://dx.doi.org/10.1093/infdis/129.1.53.
78. Safe LM, Safe SH, Subden RE, Morris DC. 1977. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can. J. Microbiol. 23:398-401. http://dx.doi.org/10.1139/m77-058.
79. Merz WG, Sandford GR. 1979. Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J. Clin. Microbiol. 9:677-680.
80. Kelly SL, Lamb DC, Taylor M, Corran AJ, Baldwin BC, Powderly WG. 1994. Resistance to amphotericin B associated with defective sterol delta 8→7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122:39-42. http://dx.doi.org/10.1111/j.1574-6968.1994.tb07140.x.
81. Vandeputte P, Tronchin G, Bergès T, Hennequin C, Chabasse D, Bouchara JP. 2007. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob. Agents Chemother. 51:982-990. http://dx.doi.org/10.1128/AAC.01510-06.
82. Ghannoum MA, Rice LB. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12:501-517.
83. Joseph-Horne T, Loeffler RS, Hollomon DW, Kelly SL. 1996. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J. Med. Vet. Mycol. 34:223-225. http://dx.doi.org/10.1080/02681219680000381.
84. Joseph-Horne T, Manning N, Holoman D, Kelly S. 1996. Nonsterol related resistance in Ustilago maydis to the polyene antifungals, amphotericin B and nystatin. Phytochemistry 42:637-639. http://dx.doi.org/10.1016/0031-9422(96)00037-4.
85. Dannaoui E, Borel E, Persat F, Piens MA, Picot S. 2000. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J. Med. Microbiol. 49:601-606.
86. Blum G, Hörtnagl C, Jukic E, Erbeznik T, Pümpel T, Dietrich H, Nagl M, Speth C, Rambach G, Lass-Flörl C. 2013. New insight into amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother. 57:1583-1588. http://dx.doi.org/10.1128/AAC.01283-12.
87. Blum G, Kainzner B, Grif K, Dietrich H, Zelger B, Sonnweber T, Lass-Flörl C. 2013. In vitro and in vivo role of heat shock protein 90 in amphotericin B resistance of Aspergillus terreus. Clin. Microbiol. Infect. 19:50-55. http://dx.doi.org/10.1111/j.1469-0691.2012.03848.x.
88. Blum G, Perkhofer S, Haas H, Schrettl M, Würzner R, Dierich MP, Lass-Flörl C. 2008. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother. 52:1553-1555. http://dx.doi.org/10.1128/AAC.01280-07.
89. Gillum AM, Tsay EY, Kirsch DR. 1984. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 198:179-182. http://dx.doi.org/10.1007/BF00328721.
90. Kwon-Chung KJ. 1976. Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia 68:821-833. http://dx.doi.org/10.2307/3758800.
91. Nielsen K, Cox GM, Wang P, Toffaletti DL, Perfect JR, Heitman J. 2003. Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect. Immun. 71:4831-4841. http://dx.doi.org/10.1128/IAI.71.9.4831-4841.2003.
92. Perfect JR, Lang SD, Durack DT. 1980. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am. J. Pathol. 101:177-194.
93. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, Macdougall L, Boekhout T, Kwon-Chung KJ, Meyer W. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. U. S. A. 101:17258-17263. http://dx.doi.org/10.1073/pnas.0402981101.
94. Varma A, Kwon-Chung KJ. 2010. Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob. Agents Chemother. 54:2303-2311. http://dx.doi.org/10.1128/AAC.00153-10.